Why fosfomycin trometamol as first line therapy for uncomplicated UTI?

International Journal of Antimicrobial Agents

Volumn 22, Issue SUPPL. 2, 2003, Pages 79-83

  Schito, G C ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Fosfomycin trometamol; Resistance; Therapy; Uncomplicated UTI

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN TROMETAMOL; NITROFURANTOIN; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; BIOFILM; DRUG ACTIVITY; DRUG CHOICE; DRUG MECHANISM; DRUG SENSITIVITY; ESCHERICHIA COLI; GRAM NEGATIVE AEROBIC RODS AND COCCI; HUMAN; NONHUMAN; PRIORITY JOURNAL; URINARY TRACT INFECTION;

EID: 0141869944     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00231-0     Document Type: Article

References (23)

1. Stamm W.E., Norrby S.R. Urinary tract infections: disease panorama and challenges. J. Infect. Dis. 183:(Suppl. 1):2001;1-4.
2. McDermott S., Daguise V., Mann H., Szweijbka L., Callaghan W. Perinatal risk for mortality and mental retardation associated with maternal urinary-tract infections. J. Fam. Pract. (2)50:2001;433-437.
3. Warren J.W. Practice guidelines for the treatment of uncomplicated cystitis. Curr. Urol. Rep. 2001;326-329.
4. Nicolle L.E. Urinary tract infection: traditional pharmacologic therapies. Am. J. Med. 113:(Suppl. 1A):2002;35-44.
5. Naber KG. Treatment options for acute uncomplicated cystitis in adults. J Antimicrob Chemother 46(Suppl 1):23-7.
6. Marchese A, Gualco L, Debbia EA, Schito GC, Schito AM. In vitro activity of fosfomycin trometamol against Gram-negative urinary pathogens and biological cost of fosfomycin trometamol resistance. Int J Antimicrob Ag 2003;21: S0924-8579(03)00230.
7. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, fourth ed. Approved Standard M7-A5 (2002) and M100-S12 (2002). NCCLS, Wayne, PA.
8. Schito G.C., Chezzi C., Nicoletti G., et al. Susceptibility of frequent urinary pathogens to fosfomycin trometamol and eight other antibiotics: results of an Italian multicenter survey. Infection. 20:(Suppl. 4):1992;291-295.
9. Gales A.C., Jones R.N., Gordon K.A., et al. Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalised patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program 1998. J. Antimicrob. Chemother. 45:2000;295-303.
10. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO. SENS project. J. Antimicrob. Chemother. 51:2003;69-76.
11. Goettsch W., van Pelt W., Nagelkerke N., et al. Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in the Netherlands. J. Antimicrob. Chemother. 46:2000;223-228.
12. Daza R., Gutierrez J., Piedrola G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int. J. Antimicrob. Agents. 18:2001;211-215.
13. Bouza E., San Juan R., Munoz P., et al. A European perspective on nosocomial urinary tract infections II. Report on incidence, clinical characteristics and outcome (ESGNI-004 study). European Study Group on Nosocomial Infection. Clin. Microbiol. Infect. 7:2001;532-542.
14. Gupta K., Sahm D.F., Mayfield D., et al. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin. Infect. Dis. 33:2001;89-94.
15. Karlowsky J.A., Kelly L.J., Thornsberry C., et al. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob. Agents Chemother. 46:2002;2540-2545.
16. Fuchs P.C., Barry A.L., Brown S.D. Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods. J. Antimicrob. Chemother. 43:1999;137-140.
17. Kobayashi S., Kuzuyama T., Seto H. Characterization of the fomA and fomB gene products from Streptomyces wedmorensis, which confer fosfomycin trometamol resistance on Escherichia coli. Antimicrob. Agents Chemother. 44:2000;647-650.
18. Kumon H. Management of biofilm infections in the urinary tract. World J. Surg. 10:2000;1193-1196.
19. Marchese A, Bozzolasco M, Gualco L, Debbia EA, Schito GC, Schito AM. Effect of fosfomycin trometamol alone and in combination with N-acetylcysteine on E. coli biofilms. Int J Antimicrob Ag, 2003;21: S0924-8579(03)00232-2 .
20. Reeves D.S. Fosfomycin trometamol. J. Antimicrob. Chemother. 34:1994;853-858.
21. Li Pira G., Pruzzo C., Schito G.C. Monuril and modification of pathogenicity traits in resistant microorganisms. Eur. Urol. 13:(Suppl. 1):1987;92-97.
22. Crampton S.E., Gerke C., Catz F. In vitro methods to study biofilm formation. Methods Enzymol. 336:2001;239-255.
23. Lobel B. Clinical outcomes in uncomplicated urinary tract infections with fosfomycin trometamol. 4th International symposium on perspectives in clinical microbiology and infections. Venice, 2003.